Search for content, post, videos

Camurus announces stronger than expected sales during the first half of 2020

Fredrik Tiberg

Camurus  has announced revised full year 2020 guidance for the company’s revenue and product sales.

Camurus’ guidance for net revenue is increased to SEK 340–380 million from SEK 290–330 million with estimated product sales of SEK 310–340 million, previously SEK 240–280 million. The improvements are driven by increasing market shares of Buvidal for treatment of opioid dependence in Europe and Australia.

Operating expenses are expected amount to SEK 570–610 million.

“After stronger than expected sales of Buvidal during the first half of 2020, we are raising our revenue and product sales guidance and are expecting a corresponding improvement of the full year results,” said Fredrik Tiberg, President & CEO of Camurus. “The Covid-19 pandemic has had both positive and negative impact on the business. It has been a catalyst for uptake in clinics with experience of Buvidal, however, has also limited access to healthcare professionals and delayed the treatment initiation of new patients and switching of patients to Buvidal in some markets.”

Photo of Fredrik Tiberg: Lars Owesson © Camurus AB